Status:
COMPLETED
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Lead Sponsor:
University of Wisconsin, Madison
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
40-72 years
Phase:
PHASE2
Brief Summary
The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High a...
Detailed Description
Studies show that some medicines that lower cholesterol may reduce the risk of developing Alzheimer's disease, but this has not yet been proven in humans. We are looking for individuals to participate...
Eligibility Criteria
Inclusion
- Parent diagnosed with Alzheimer's disease
- Age 40-72
Exclusion
- Active liver disease
- History of adverse reaction to statins
- Contraindication to lumbar puncture
- Elevated creatine kinase and creatinine lab values
- Use of medications known to interact with statins
- History of dementia or mild cognitive impairment
- Currently pregnant or planning to become pregnant
- Use of large quantities of grapefruit juice (more than 1 quart per day)
- Contraindications to MRI (for MRI sub-study)
- Currently on cholesterol-lowering medication or use in past 4 months
- History of heart attack, heart problems, stroke and/or diabetes
- Drinking more than a quart of grapefruit juice per day
- Metal implants, or metal debris in body (MRI)
- List of medications that interact with simvastatin
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00939822
Start Date
March 1 2009
End Date
September 1 2013
Last Update
August 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karen Lazar
Fitchburg, Wisconsin, United States, 53711